Overview
The GH Release Bundle combines two well-studied research peptides — CJC-1295 (No DAC) and Ipamorelin — that act through complementary mechanisms within growth hormone–related signaling pathways. In laboratory research settings, this pairing allows investigation into coordinated GHRH and GHRP signaling dynamics within controlled experimental systems.
This bundle is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
Each component of the GH Release Bundle contributes a distinct signaling role:
CJC-1295 (No DAC) (5mg) — studied as a growth hormone–releasing hormone (GHRH) analog for short-acting, pulsatile signaling dynamics
Ipamorelin (5mg) — investigated as a selective growth hormone–releasing peptide (GHRP) that engages ghrelin receptor–mediated signaling pathways
Together, these peptides allow researchers to examine how parallel GHRH and GHRP signaling mechanisms interact within growth hormone research models.
Research Context
Research investigations involving the GH Release Bundle commonly explore:
Coordinated growth hormone signaling pathways
Pulsatile endocrine signaling frameworks
Comparative studies of single-pathway versus dual-pathway stimulation
Interaction between GHRH and ghrelin receptor signaling mechanisms
These investigations remain limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
Researchers evaluating this bundle often review the individual components — CJC-1295 (No DAC) Peptide and Ipamorelin Peptide — as well as alternative GH-axis research compounds such as CJC-1295 (DAC) Peptide.
